The news: Utah’s medical licensing board is urging a halt to a state pilot that aims to use AI to renew certain prescriptions without physician oversight.

For context, Utah’s Office of Artificial Intelligence Policy and health tech firm Doctronic are piloting a program where AI assesses patients and issues refills for nearly 200 non-controlled medications without doctor approval. A letter from Utah’s medical licensing board last week, signed by 11 clinicians, says they learned of the pilot only after it launched and recommends suspending it pending further review.

Why it matters: The debate over continuing the program boils down to two competing ideas: technology’s ability to provide patients with quicker access to care versus concerns about whether AI is ready to make clinical decisions on its own.

Doctronic and Utah’s AI office say the program targets a major healthcare access gap and has safety measures in place. Doctronic argued that a shortage of primary care physicians is expected to worsen and is already causing delays in medication renewals. This creates a gap that AI can fill, allowing doctors to focus on more complex clinical care instead of routine refill appointments. Utah officials said Doctronic’s AI is not yet autonomously renewing prescriptions, as the pilot remains in phase one in which human clinician review is required.

Clinicians emphasize the need for caution when handling high-stakes patient issues such as prescription drugs. Prescription refills are a clinical responsibility reserved for licensed physicians, who must assess dosing changes, side effects, and potential drug interactions, per the medical licensing board. For context, neither Doctronic nor any other AI tool is licensed to practice medicine in the US.

Implications for healthcare AI companies: Utah is the first state to approve AI for automated prescription renewals, though the program isn’t fully autonomous yet. The high-profile attention around this pilot may make other states hesitant to follow in the near term unless there’s tangible evidence that AI improves medication access without compromising safety compared with human clinicians. For states and tech companies that do pursue similar AI initiatives related to practicing medicine, early engagement with medical boards is critical—giving physicians a voice in the process can help ease concerns and build trust.

This content is part of EMARKETER’s subscription Briefings, where we pair daily updates with data and analysis from forecasts and research reports. Our Briefings prepare you to start your day informed, to provide critical insights in an important meeting, and to understand the context of what’s happening in your industry. Not a subscriber? Click here to get a demo of our full platform and coverage.